H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 85 Citations 28,679 403 World Ranking 7607 National Ranking 233

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Surgery

His primary areas of investigation include Internal medicine, Lung cancer, Oncology, Surgery and Radiology. His Internal medicine research incorporates elements of Gastroenterology and Endocrinology. His Lung cancer research is multidisciplinary, incorporating perspectives in Cancer, Clinical trial, Incidence, Randomized controlled trial and Lung.

His work in the fields of Adenocarcinoma and Atezolizumab overlaps with other areas such as Monoclonal. The concepts of his Oncology study are interwoven with issues in Carboplatin, Clinical endpoint, Pharmacology and Circulating tumor cell. His Surgery study integrates concerns from other disciplines, such as Quality and Adverse effect.

His most cited work include:

  • Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer (845 citations)
  • Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials (778 citations)
  • Multiple common variants for celiac disease influencing immune gene expression (739 citations)

What are the main themes of his work throughout his whole career to date?

His primary scientific interests are in Internal medicine, Lung cancer, Oncology, Surgery and Cancer research. His Internal medicine study frequently links to adjacent areas such as Gastroenterology. His work carried out in the field of Lung cancer brings together such families of science as Cancer, Adenocarcinoma and Radiology, Radiation therapy.

Harry J.M. Groen interconnects Stage and Lung in the investigation of issues within Radiology. His Oncology study deals with Carboplatin intersecting with Bevacizumab. As part of his studies on Surgery, Harry J.M. Groen often connects relevant areas like Clinical trial.

He most often published in these fields:

  • Internal medicine (49.16%)
  • Lung cancer (44.69%)
  • Oncology (33.15%)

What were the highlights of his more recent work (between 2017-2021)?

  • Lung cancer (44.69%)
  • Internal medicine (49.16%)
  • Oncology (33.15%)

In recent papers he was focusing on the following fields of study:

Lung cancer, Internal medicine, Oncology, Cancer research and Non small cell are his primary areas of study. His Lung cancer research is multidisciplinary, incorporating elements of Lung, Radiology, Circulating tumor cell and Adenocarcinoma. In the subject of general Internal medicine, his work in Chemotherapy, Cancer and Conventional PCI is often linked to In patient, thereby combining diverse domains of study.

Harry J.M. Groen has included themes like Positron emission tomography, Biopsy, Clinical trial and Carcinoma in his Cancer study. His work deals with themes such as Phases of clinical research and Hazard ratio, which intersect with Oncology. His Cancer research research includes elements of Pd l1 expression, Immune checkpoint inhibitors, Predictive biomarker, Gefitinib and Crizotinib.

Between 2017 and 2021, his most popular works were:

  • Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial (358 citations)
  • 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. (172 citations)
  • Capmatinib (INC280) in MET Delta exI4-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. (64 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

Harry J.M. Groen mainly focuses on Lung cancer, Internal medicine, Oncology, non-small cell lung cancer and Radiology. His Lung cancer research is mostly focused on the topic Erlotinib. His research on Internal medicine often connects related topics like Gastroenterology.

His study in Oncology is interdisciplinary in nature, drawing from both Cancer, Adverse effect, Biodistribution and Hazard ratio. His biological study spans a wide range of topics, including Brain lesions and Capmatinib. His research in Radiology intersects with topics in Lung, Incidence and Disease.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Joe Y Chang;Suresh Senan;Marinus A. Paul;Reza John Mehran.
Lancet Oncology (2015)

1142 Citations

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George.
Nature Genetics (2012)

1064 Citations

Multiple common variants for celiac disease influencing immune gene expression

Patrick C. A. Dubois;Gosia Trynka;Lude Franke;Lude Franke;Karen A. Hunt.
Nature Genetics (2010)

923 Citations

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer.
Science Translational Medicine (2010)

869 Citations

Management of lung nodules detected by volume CT scanning

Rob J van Klaveren;Matthijs Oudkerk;Mathias Prokop;Ernst T Scholten.
The New England Journal of Medicine (2009)

853 Citations

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard;Egbert F Smit;Harry J M Groen;Julien Mazieres.
Lancet Oncology (2016)

556 Citations

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Peter S. Hammerman;Martin L. Sos;Alex H. Ramos;Chunxiao Xu.
Cancer Discovery (2011)

533 Citations

A genomics-based classification of human lung tumors

Danila Seidel;Thomas Zander;Lukas C. Heukamp;Martin Peifer.
Science Translational Medicine (2013)

517 Citations

Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial

Harry J de Koning;Carlijn M van der Aalst;Pim A de Jong;Ernst T Scholten.
The New England Journal of Medicine (2020)

468 Citations

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Dong Wan Kim;Dong Wan Kim;Marcello Tiseo;Myung Ju Ahn;Karen L. Reckamp.
Journal of Clinical Oncology (2017)

421 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Harry J.M. Groen

Cisca Wijmenga

Cisca Wijmenga

University Medical Center Groningen

Publications: 84

Matthijs Oudkerk

Matthijs Oudkerk

University of Groningen

Publications: 77

Lude Franke

Lude Franke

University Medical Center Groningen

Publications: 74

Benjamin Besse

Benjamin Besse

Institut Gustave Roussy

Publications: 74

Edwin K. Silverman

Edwin K. Silverman

Brigham and Women's Hospital

Publications: 71

Suresh Senan

Suresh Senan

University of Amsterdam

Publications: 69

Ming-Sound Tsao

Ming-Sound Tsao

Princess Margaret Cancer Centre

Publications: 66

Mathias Prokop

Mathias Prokop

Radboud University Nijmegen

Publications: 62

Bram van Ginneken

Bram van Ginneken

Radboud University Nijmegen

Publications: 61

Dirk De Ruysscher

Dirk De Ruysscher

Maastricht University

Publications: 60

John K. Field

John K. Field

University of Liverpool

Publications: 55

Fabrice Barlesi

Fabrice Barlesi

Aix-Marseille University

Publications: 55

Rafael Rosell

Rafael Rosell

Autonomous University of Barcelona

Publications: 50

Bruce M. Psaty

Bruce M. Psaty

University of Washington

Publications: 48

Egbert F. Smit

Egbert F. Smit

VU University Medical Center

Publications: 48

Roman K. Thomas

Roman K. Thomas

University of Cologne

Publications: 47

Something went wrong. Please try again later.